References of "REGINSTER, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPatients at high risk of hip fracture benefit from treatment with strontium ranelate
Rizzoli, R.; Reginster, Jean-Yves ULg; Diaz-Curiel, M. et al

in Calcified Tissue International (2004), 74(S1), 83-84

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent vertebral fracture
Reginster, Jean-Yves ULg; Rizzoli, R.; Balogh, A. et al

in Calcified Tissue International (2004), 74(S1), 83

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailResponders to glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Pavelka, Karel; Richy, Florent et al

in Arthritis and Rheumatism (2004), 50(suppl.1), 29

Detailed reference viewed: 13 (4 ULg)
Full Text
Peer Reviewed
See detailA critical analysis of the efficacy of estrogens on spinal and non-spinal fracture reduction
REGINSTER, Jean-Yves ULg; Richy, Florent; Bruyère, Olivier ULg

in Reproduction Humaine et Hormones (2004), XVII(5), 419-423

During more than 20 years, estrogens replacement therapy (ERT) has been consistently regarded as the first choice for prevention of trabecular and cortical bone loss in postmenopausal women. However ... [more ▼]

During more than 20 years, estrogens replacement therapy (ERT) has been consistently regarded as the first choice for prevention of trabecular and cortical bone loss in postmenopausal women. However, there are more doubts upon the unequivocal demonstration of the anti-fracture efficacy of ERT, at the spine and hip. Controlled clinical trials and systematic reviews were retrieved, using Medline 1970-2002 and EMBASE 1980-2002. There is a convergent body of evidence that estrogens could significantly reduce the risk of vertebral and non-vertebral fractures, providing this treatment is started early after the menopause and pursued indefinitely. In the recent perspective of the published studies, reevaluating the non-skeletal benefits and harms of ERT in post-menopausal women, other chemical entities might be better options to be used for the specific purpose of preventing or treating post-menopausal osteoporosis. [less ▲]

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailOsteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate
Christgau, Stephan; Henrotin, Yves ULg; Tanko, Laszlo B et al

in Clinical and Experimental Rheumatology (2004), 22(1, JAN-FEB), 36-42

Objective Glucosamine sulphate has been shown in a large double-blind, placebo-controlled clinical trial to prevent structural damage and improve clinical symptoms of osteoarthritis (OA). We investigated ... [more ▼]

Objective Glucosamine sulphate has been shown in a large double-blind, placebo-controlled clinical trial to prevent structural damage and improve clinical symptoms of osteoarthritis (OA). We investigated whether early response in a newly developed biochemical marker of collagen type II degradation (CTX-II, CartiLaps ELISA) could reflect the long-term preservation of hyaline cartilage. Methods Study subjects comprised 212 knee OA patients participating in a clinical trial of the effects of glucosamine sulphate. Disease symptoms were assessed quarterly by WOMAC scoring and X-ray analysis was performed at baseline and after 3 years. Urine samples were obtained at baseline and after 1, 2 and 3 years for measurement in the CartiLaps assay. The measurements were corrected for creatinine. Results At baseline the patients had an average concentration of urinary CTX-II of 222.4 +/- 159.5 ng/mmol creatinine. This was significantly above the CTX-II levels measured in urine samples from 415 healthy controls (169.1 +/- 92.3 ng/mmol, p < 0.0001). There was no significant difference in the CTX-II response in the placebo group and the glucosamine treated group. However, those with high cartilage turnover presented a significant decrease in CTX-II after 12-month glucosamine treatment. Thus, thee group with CTX II concentrations above normal average + ISD decreased 15.5 % after 12-month therapy. The 12 months change in CTX-II in OA patients with elevated CTX-II at baseline correlated with the change in average joint space width observed after 36 months (R = 0.43, p < 0.05). Increased baseline levels of CTX-II were associated with a worsening of the WOMAC index (p < 0.01). Conclusion The data indicate that measurement of urinary collagen type H C-telopeptide fragments enables the identification of OA patients with high cartilage turnover who at the same time are most responsive to therapy with structure modifying drugs. [less ▲]

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailGlucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies
Bruyère, Olivier ULg; Pavelka, K.; Rovati, Lucio C et al

in Menopause (2004), 11(2), 138-143

OBJECTIVE: To investigate the effect of glucosamine sulfate on long-term symptoms and structure progression in postmenopausal women with knee osteoarthritis (OA). DESIGN: This study consisted of a ... [more ▼]

OBJECTIVE: To investigate the effect of glucosamine sulfate on long-term symptoms and structure progression in postmenopausal women with knee osteoarthritis (OA). DESIGN: This study consisted of a preplanned combination of two three-year, randomized, placebo-controlled, prospective, independent studies evaluating the effect of glucosamine sulfate on symptoms and structure modification in OA and post-hoc analysis of the results obtained in postmenopausal women with knee OA. Minimal joint space width was assessed at baseline and after 3 years from standing anteroposterior knee radiographs. Symptoms were scored by the algo-functional WOMAC index at baseline and after 3 years. All primary statistical analyses were performed in intention-to-treat, comparing joint space width and WOMAC changes between groups by ANOVA. RESULTS: Of 414 participants randomized in the two studies, 319 were postmenopausal women. At baseline, glucosamine sulfate and placebo groups were comparable for demographic and disease characteristics, both in the general population and in the postmenopausal women subset. After 3 years, postmenopausal participants in the glucosamine sulfate group showed no joint space narrowing [joint space change of +0.003 mm (95% CI, -0.09 to 0.11)], whereas participants in the placebo group experienced a narrowing of -0.33 mm (95% CI, -0.44 to -0.22; P < 0.0001 between the two groups). Percent changes after 3 years in the WOMAC index showed an improvement in the glucosamine sulfate group [-14.1% (95%, -22.2 to -5.9)] and a trend for worsening in the placebo group (5.4% (95% CI, -4.9 to 15.7) (P = 0.003 between the two groups). CONCLUSION: This analysis, focusing on a large cohort of postmenopausal women, demonstrated for the first time that a pharmacological intervention for OA has a disease-modifying effect in this particular population, the most frequently affected by knee OA. [less ▲]

Detailed reference viewed: 19 (3 ULg)
Full Text
Peer Reviewed
See detailAge- and sex-stratified prevalence of physical disabilities and handicap in the general population.
Ethgen, Olivier ULg; Gillain, Daniel ULg; Gillet, Pierre ULg et al

in Aging Clinical & Experimental Research (2004), 16(5), 389-97

BACKGROUND AND AIMS: Our aim was to provide age- and sex-stratified prevalence estimates of physical disabilities and handicap in the general Belgian population. METHODS: A cross-sectional and ... [more ▼]

BACKGROUND AND AIMS: Our aim was to provide age- and sex-stratified prevalence estimates of physical disabilities and handicap in the general Belgian population. METHODS: A cross-sectional and demographically representative health interview survey was conducted nationwide in Belgium in 1997. The 8836 persons aged 15 years and over who answered the health interview were included in this study. Seventeen items from the survey encompassing main activities of daily living (ADL) and confining were analyzed. To provide prevalence estimates as detailed as possible, neither aggregation nor dichotomization were applied. RESULTS: Women consistently reported more disability than men: mobility (p < 0.001), transfer in-out bed (p < 0.001), transfer in-out chair (p < 0.001), dressing (p = 0.004), washing hands and face (p = 0.029), getting to and using toilet (p = 0.003), continence (p < 0.001), seeing (p < 0.001) and mastication (p < 0.001). As expected, there was a marked trend for increased prevalence of disability with increasing age for both sexes. Moderate disability arose mainly from the 25-34 age group for both sexes. For both genders, severe disability appeared mainly at higher ages, particularly for the 65-74 age group. Nevertheless, the data suggest that continence problems for women, mobility and transfer issues for men, as well as mastication problems for both genders, clearly emerge earlier than age 65. Regarding handicap, observed prevalence rates were increasing, in age as was the case for disability, but no differences were found between men or women, except for confinement to house/garden, for which women presented a higher rate in general (p < 0.001) and in the 75-84 age group (p = 0.036) in particular. CONCLUSIONS: This study shows the wide range of disability types in the general population and their association with handicap. While elderly individuals consistently report higher degrees of disability and handicap, attention should also be paid to younger age groups. Disability calls for wide, coherent and relevant medical as well as social responses. [less ▲]

Detailed reference viewed: 122 (12 ULg)
Full Text
Peer Reviewed
See detailSustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Lindsay, Robert; Scheele, Wim H; Neer, Robert et al

in Archives of Internal Medicine (2004), 164(18), 2024-30

BACKGROUND: Teriparatide (recombinant human parathyroid hormone [1-34]) reduces fracture risk in postmenopausal women with osteoporosis. We assessed the safety and incidence of new vertebral fractures ... [more ▼]

BACKGROUND: Teriparatide (recombinant human parathyroid hormone [1-34]) reduces fracture risk in postmenopausal women with osteoporosis. We assessed the safety and incidence of new vertebral fractures after withdrawal of teriparatide. METHODS: This study is a follow-up to the Fracture Prevention Trial (FPT), a randomized, placebo-controlled study of postmenopausal women with osteoporosis treated with teriparatide (20 or 40 microg) once daily for a mean of 18 months. More than 90% of the women remaining at the end of the FPT continued into the follow-up study (n = 1262). Patients and investigators were unblinded to original treatment group assignment. Women were treated according to standard clinical practice, including elective use of osteoporosis drugs. New vertebral fractures were determined by semiquantitative scoring of lateral thoracic lumbar spine radiographs 18 months after the end of the FPT. RESULTS: During the follow-up study, the reduction in fracture risk associated with previous treatment with teriparatide, 20 and 40 microg, was 41% (P = .004) and 45% (P = .001), respectively, vs placebo. The absolute reduction from the FPT baseline to the 18-month follow-up visit was 13% for both doses. Osteoporosis drugs were used by 47% of women during follow-up, with greater use in the former placebo group (P = .04); nevertheless, persistent fracture protection of previous teriparatide therapy was evident. Post hoc analysis also suggests that teriparatide treatment substantially reduced the increased risk of subsequent fracture in women who sustained a fracture during the FPT (P = .05). CONCLUSION: Vertebral fracture risk reduction by teriparatide administration persists for at least 18 months after discontinuation of therapy. [less ▲]

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailRégulation du Métabolisme des Chondrocytes par l'Oncostatine M et l'Interleukine 6
Sanchez, Christelle ULg; Deberg, Michelle ULg; Devel, Philippe et al

in Revue du Rhumatisme (2004), 71(10-11), 1008

Detailed reference viewed: 30 (4 ULg)
Full Text
Peer Reviewed
See detailSubchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes
Sanchez, Christelle ULg; Deberg, Michelle ULg; Piccardi, Nathalie et al

in Osteoarthritis and Cartilage (2004), 12(Suppl. B), 99-100

Detailed reference viewed: 10 (3 ULg)
Full Text
Peer Reviewed
See detailFuranic avocado/soybean unsaponifiables prevent osteoarthritic subchondral osteoblasts-induced cartilage degradation
Sanchez, Christelle ULg; Deberg, Michelle ULg; Piccardi, Nathalie et al

in Osteoarthritis and Cartilage (2004), 12(Suppl. B), 108-109

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailInterleukin-1, interleukin-6 and oncostatin M stimulate normal subchondral osteoblasts to induce cartilage degradation
Sanchez, Christelle ULg; Deberg, Michelle ULg; Piccardi, Nathalie et al

in Osteoarthritis and Cartilage (2004), 12(Suppl. B), 98

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailPharmacodynamics of follicle stimulating hormone (FSH) in postmenopausal women during pulsed estrogen therapy: Evidence that FSH release and synthesis are controlled by distinct pathways
Christin-Maitre, S.; Laveille, C.; Collette, Julien ULg et al

in Journal of Clinical Endocrinology and Metabolism (2003), 88(11), 5405-5413

17beta-Estradiol (E2) exerts negative feedback effects at the hypothalamo-pituitary level on serum FSH. This study investigated the effects of repeated daily administration of intranasal E2 (S21400) on ... [more ▼]

17beta-Estradiol (E2) exerts negative feedback effects at the hypothalamo-pituitary level on serum FSH. This study investigated the effects of repeated daily administration of intranasal E2 (S21400) on the pharmacokinetics (PK) of E2 and estrone (E1) and the pharmacodynamics (PD) of FSH and assessed the PK/PD relationship between E2 and FSH using population model-dependent analysis. Postmenopausal volunteers (n = 24) received according to a balanced cross-over design, two 28-d treatments separated by a 2-month wash-out period: 300 mug E2, either alone or combined with oral dydrogesterone (20 mg/d) during the last 14 d of one of the treatments. Absorption of E2 was rapid, with maximal plasma concentrations at 10-30 min, returning to postmenopausal levels within 12 h. Over the 24-h period, FSH levels showed a U curve, with a minimum around 8 h after E2 administration. Moreover, over the treatment period, FSH basal values decreased by 17% between d 1 and 14 and an additional 5% between d 14 and 28. A PK/PD model described these short- and mid-term effects, possibly reflecting separate regulation mechanisms by E2 on FSH release and biosynthesis, respectively. The administration of progestin had no influence on E1, E2, and FSH model parameters. This study suggests that daily transient tissue exposure to E2 after pulsed estrogen therapy elicits short- and mid-term effects on the gonadotropin axis. [less ▲]

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailTime-dependent risk of gastrointestinal complications induced by NSAIDS use: a consensus statement using meta-analytic approach
Richy, Florent; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 9

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailDo new methods of investigation allow faster assessment of drugs efficacy in osteoarthritis?
Abadie, Eric ULg; Avouac, B.; Bouvenot, G. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 2

Detailed reference viewed: 19 (2 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the relationship between IGF-I, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign
Hanssens, L.; Tancredi, Annalisa ULg; De Ceulaer, F. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 90-91

Detailed reference viewed: 29 (10 ULg)